A pharmacokinetic-pharmacodynamic model for a muscle relaxant: Atracurium

V. Nigrovic, J. Gaspari, M. Banoub

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Our goal was to develop a pharmacokinetic-pharmacodynamic model that describes the fate of atracurium and its metabolite laudanosine as well as the time course of the neuromuscular block. The model was based on the consideration of mass balance of atracurium and was constructed by postulating an effect compartment linked to the central compartment in the previously described open mammillary model for atracurium. The entry and exit rate constants, k(CE) and k(EC), were adjusted to satisfy the requirement that the peak amount in the effect compartment coincides with the peak submaximal block. We used previously published clinical data to arrive at the times to 50% neuromuscular block either during the onset of the block following an ED50 dose or during the recovery following larger doses of atracurium. Laplace transforms were used to define the model, and the solution was obtained by iterative numeric adjustments of the rate constants. The model provides an excellent fit of the observed plasma concentrations of atracurium and laudanosine and simulates well the development and waning of the neuromuscular block. The model projects that the peak amount of atracurium in the effect compartment amounts to 14% of the injected dose and is reached at 7.6 min after the injection.

Original languageEnglish (US)
Pages (from-to)325-332
Number of pages8
JournalEuropean Journal of Clinical Pharmacology
Volume49
Issue number4
StatePublished - Jan 30 1996

Fingerprint

Atracurium
Pharmacokinetics
Muscles
Neuromuscular Blockade
Injections

Keywords

  • Atracurium
  • Effect compartment
  • Muscle relaxants
  • Pharmacokinetic-pharmacodynamic model

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

A pharmacokinetic-pharmacodynamic model for a muscle relaxant : Atracurium. / Nigrovic, V.; Gaspari, J.; Banoub, M.

In: European Journal of Clinical Pharmacology, Vol. 49, No. 4, 30.01.1996, p. 325-332.

Research output: Contribution to journalArticle

Nigrovic, V, Gaspari, J & Banoub, M 1996, 'A pharmacokinetic-pharmacodynamic model for a muscle relaxant: Atracurium', European Journal of Clinical Pharmacology, vol. 49, no. 4, pp. 325-332.
Nigrovic, V. ; Gaspari, J. ; Banoub, M. / A pharmacokinetic-pharmacodynamic model for a muscle relaxant : Atracurium. In: European Journal of Clinical Pharmacology. 1996 ; Vol. 49, No. 4. pp. 325-332.
@article{8fddf6032eb64af38d2db86f9d5311e4,
title = "A pharmacokinetic-pharmacodynamic model for a muscle relaxant: Atracurium",
abstract = "Our goal was to develop a pharmacokinetic-pharmacodynamic model that describes the fate of atracurium and its metabolite laudanosine as well as the time course of the neuromuscular block. The model was based on the consideration of mass balance of atracurium and was constructed by postulating an effect compartment linked to the central compartment in the previously described open mammillary model for atracurium. The entry and exit rate constants, k(CE) and k(EC), were adjusted to satisfy the requirement that the peak amount in the effect compartment coincides with the peak submaximal block. We used previously published clinical data to arrive at the times to 50{\%} neuromuscular block either during the onset of the block following an ED50 dose or during the recovery following larger doses of atracurium. Laplace transforms were used to define the model, and the solution was obtained by iterative numeric adjustments of the rate constants. The model provides an excellent fit of the observed plasma concentrations of atracurium and laudanosine and simulates well the development and waning of the neuromuscular block. The model projects that the peak amount of atracurium in the effect compartment amounts to 14{\%} of the injected dose and is reached at 7.6 min after the injection.",
keywords = "Atracurium, Effect compartment, Muscle relaxants, Pharmacokinetic-pharmacodynamic model",
author = "V. Nigrovic and J. Gaspari and M. Banoub",
year = "1996",
month = "1",
day = "30",
language = "English (US)",
volume = "49",
pages = "325--332",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - A pharmacokinetic-pharmacodynamic model for a muscle relaxant

T2 - Atracurium

AU - Nigrovic, V.

AU - Gaspari, J.

AU - Banoub, M.

PY - 1996/1/30

Y1 - 1996/1/30

N2 - Our goal was to develop a pharmacokinetic-pharmacodynamic model that describes the fate of atracurium and its metabolite laudanosine as well as the time course of the neuromuscular block. The model was based on the consideration of mass balance of atracurium and was constructed by postulating an effect compartment linked to the central compartment in the previously described open mammillary model for atracurium. The entry and exit rate constants, k(CE) and k(EC), were adjusted to satisfy the requirement that the peak amount in the effect compartment coincides with the peak submaximal block. We used previously published clinical data to arrive at the times to 50% neuromuscular block either during the onset of the block following an ED50 dose or during the recovery following larger doses of atracurium. Laplace transforms were used to define the model, and the solution was obtained by iterative numeric adjustments of the rate constants. The model provides an excellent fit of the observed plasma concentrations of atracurium and laudanosine and simulates well the development and waning of the neuromuscular block. The model projects that the peak amount of atracurium in the effect compartment amounts to 14% of the injected dose and is reached at 7.6 min after the injection.

AB - Our goal was to develop a pharmacokinetic-pharmacodynamic model that describes the fate of atracurium and its metabolite laudanosine as well as the time course of the neuromuscular block. The model was based on the consideration of mass balance of atracurium and was constructed by postulating an effect compartment linked to the central compartment in the previously described open mammillary model for atracurium. The entry and exit rate constants, k(CE) and k(EC), were adjusted to satisfy the requirement that the peak amount in the effect compartment coincides with the peak submaximal block. We used previously published clinical data to arrive at the times to 50% neuromuscular block either during the onset of the block following an ED50 dose or during the recovery following larger doses of atracurium. Laplace transforms were used to define the model, and the solution was obtained by iterative numeric adjustments of the rate constants. The model provides an excellent fit of the observed plasma concentrations of atracurium and laudanosine and simulates well the development and waning of the neuromuscular block. The model projects that the peak amount of atracurium in the effect compartment amounts to 14% of the injected dose and is reached at 7.6 min after the injection.

KW - Atracurium

KW - Effect compartment

KW - Muscle relaxants

KW - Pharmacokinetic-pharmacodynamic model

UR - http://www.scopus.com/inward/record.url?scp=0030068726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030068726&partnerID=8YFLogxK

M3 - Article

C2 - 8857080

AN - SCOPUS:0030068726

VL - 49

SP - 325

EP - 332

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 4

ER -